window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-4PR1PSYQLJ'); Skip to content

Welcome to Discover Pharma! Today is : November 16, 2025

  • News
  • About Us
Contact Us

EMA

  • Drug approval,Oncology,Pharmaceuticals and therapeutics

    Otsuka submits EMA application for Inaqovi and venetoclax combination to treat acute myeloid leukaemia

    Otsuka Pharmaceutical Europe has submitted a marketing authorisation application (MAA) [...]

    November 7, 2025
  • Chronic diseases,Clinical Trials,Pharmaceuticals and therapeutics,Regulatory Affairs

    Tezspire recommended for EU approval for chronic rhinosinusitis with nasal polyps

    AstraZeneca and Amgen’s Tezspire (tezepelumab) has received a positive opinion [...]

    September 23, 2025
  • Biotech,Global health,Pharmaceuticals and therapeutics,Research & Development

    MaaT Pharma reports strong Phase 3 results and EMA submission for Xervyteg

    MaaT Pharma (EURONEXT: MAAT), a clinical-stage biotech focused on microbiome-based [...]

    September 22, 2025
  • Drug Development,Neurosciences,Rare Diseases,Regulatory Affairs

    SOM Biotech secures EMA orphan designation opinion for Huntington’s drug SOM3355

    Barcelona-based biotech advances Huntington’s programme as EMA backs orphan designation, [...]

    September 15, 2025
  • Clinical Trials,Global health,Oncology,Precision medicine,Rare Diseases,Regulatory Affairs,Research & Development

    CHMP backs Gilead’s twice-yearly lenacapavir for HIV prevention under accelerated EMA review

    Gilead Sciences has received a positive opinion from the Committee [...]

    July 25, 2025
  • Biologics & Biosimilars,CDMOs & Manufacturing,Cell & Gene Therapy,Regulatory Affairs

    Is Europe rising? How global pharma uncertainty is fuelling a new era for European innovation

    As global pharma grapples with shifting regulations, rising geopolitical tensions, [...]

    June 8, 2025
  • Cell & Gene Therapy,Clinical Trials,Drug Development

    MaaT Pharma submits EMA application for Xervyteg in graft-versus-host disease

    MaaT Pharma has submitted a marketing authorisation application (MAA) to [...]

    June 2, 2025
  • Artificial Intelligence,Technology and platforms,Women in Pharma

    AI governance in pharmacovigilance: Marie Flanagan calls for safety-specific frameworks to safeguard patient risk

    The integration of artificial intelligence into pharmacovigilance is prompting a [...]

    June 2, 2025
  • Clinical Trials,Drug Development,Market Access & Commercialization,Regulatory Affairs

    New study urges EU to overhaul regulatory landscape to remain competitive in pharma innovation

    Research from Bayes Business School and Merck KGaA identifies barriers [...]

    May 6, 2025

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2025 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • Clairity raises $43 million to launch FDA-authorized AI platform for breast cancer risk prediction
    Categories: Artificial Intelligence, Biotech, Clinical Development, Diagnostics, Digital Health, Drug Development, Global health, Healthcare leadership, Precision medicine, Women's Health
  • FDA approves Kura and Kyowa Kirin’s ziftomenib for relapsed or refractory AML
    Categories: Drug approval, Oncology, Pharmaceuticals and therapeutics
  • Successful treatment for ALS could deliver billions in global value
    Categories: Neurosciences, Rare Diseases, Research & Development
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details. OK
Go to Top